Summary | |
---|---|
Symbol | HGD |
Name | homogentisate 1,2-dioxygenase |
Aliases | HGO; homogentisate oxidase; AKU; homogentisate 1,2-dioxygenase (homogentisate oxidase); homogentisate oxygen ...... |
Chromosomal Location | 3q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | - |
Domain |
PF04209 homogentisate 1 |
Function |
- |
Biological Process |
GO:0006520 cellular amino acid metabolic process GO:0006558 L-phenylalanine metabolic process GO:0006559 L-phenylalanine catabolic process GO:0006570 tyrosine metabolic process GO:0006572 tyrosine catabolic process GO:0009063 cellular amino acid catabolic process GO:0009072 aromatic amino acid family metabolic process GO:0009074 aromatic amino acid family catabolic process GO:0016054 organic acid catabolic process GO:0019439 aromatic compound catabolic process GO:0044282 small molecule catabolic process GO:0046395 carboxylic acid catabolic process GO:1901361 organic cyclic compound catabolic process GO:1901565 organonitrogen compound catabolic process GO:1901605 alpha-amino acid metabolic process GO:1901606 alpha-amino acid catabolic process |
Molecular Function |
GO:0004411 homogentisate 1,2-dioxygenase activity GO:0016701 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen GO:0016702 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen GO:0051213 dioxygenase activity |
Cellular Component | - |
KEGG |
hsa00350 Tyrosine metabolism hsa01100 Metabolic pathways |
Reactome |
R-HSA-6788656: Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism R-HSA-1430728: Metabolism R-HSA-71291: Metabolism of amino acids and derivatives R-HSA-71182: Phenylalanine and tyrosine catabolism |
Summary | |
---|---|
Symbol | HGD |
Name | homogentisate 1,2-dioxygenase |
Aliases | HGO; homogentisate oxidase; AKU; homogentisate 1,2-dioxygenase (homogentisate oxidase); homogentisate oxygen ...... |
Chromosomal Location | 3q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between HGD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | HGD |
Name | homogentisate 1,2-dioxygenase |
Aliases | HGO; homogentisate oxidase; AKU; homogentisate 1,2-dioxygenase (homogentisate oxidase); homogentisate oxygen ...... |
Chromosomal Location | 3q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of HGD in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | HGD |
Name | homogentisate 1,2-dioxygenase |
Aliases | HGO; homogentisate oxidase; AKU; homogentisate 1,2-dioxygenase (homogentisate oxidase); homogentisate oxygen ...... |
Chromosomal Location | 3q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of HGD in various data sets.
|
Points in the above scatter plot represent the mutation difference of HGD in various data sets.
|
Summary | |
---|---|
Symbol | HGD |
Name | homogentisate 1,2-dioxygenase |
Aliases | HGO; homogentisate oxidase; AKU; homogentisate 1,2-dioxygenase (homogentisate oxidase); homogentisate oxygen ...... |
Chromosomal Location | 3q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HGD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | HGD |
Name | homogentisate 1,2-dioxygenase |
Aliases | HGO; homogentisate oxidase; AKU; homogentisate 1,2-dioxygenase (homogentisate oxidase); homogentisate oxygen ...... |
Chromosomal Location | 3q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HGD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HGD. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | HGD |
Name | homogentisate 1,2-dioxygenase |
Aliases | HGO; homogentisate oxidase; AKU; homogentisate 1,2-dioxygenase (homogentisate oxidase); homogentisate oxygen ...... |
Chromosomal Location | 3q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HGD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | HGD |
Name | homogentisate 1,2-dioxygenase |
Aliases | HGO; homogentisate oxidase; AKU; homogentisate 1,2-dioxygenase (homogentisate oxidase); homogentisate oxygen ...... |
Chromosomal Location | 3q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of HGD expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | HGD |
Name | homogentisate 1,2-dioxygenase |
Aliases | HGO; homogentisate oxidase; AKU; homogentisate 1,2-dioxygenase (homogentisate oxidase); homogentisate oxygen ...... |
Chromosomal Location | 3q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between HGD and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | HGD |
Name | homogentisate 1,2-dioxygenase |
Aliases | HGO; homogentisate oxidase; AKU; homogentisate 1,2-dioxygenase (homogentisate oxidase); homogentisate oxygen ...... |
Chromosomal Location | 3q |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting HGD collected from DrugBank database. |
There is no record. |